Concepedia

Hirokazu Ohsawa

HO

Statistics

Publications

7

Citations

437

H-Index

7

Active since

1993

Affiliations

Taiho Pharmaceutical (Japan)(Current)

National Institute of Advanced Industrial Science and Technology

Hirokazu Ohsawa is an author at Taiho Pharmaceutical (Japan) specializing in medicine, pharmacology, and tyrosine kinase inhibitors.

Publications per year

1993–2023

7

Publications

7

Futibatinib Is a Novel Irreversible FGFR 1–4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors

Hiroshi Sootome, Hidenori Fujita, Kenjiro Ito et al. · Cancer Research · 2020 · 198 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations

Shinichi Hasako, Miki Terasaka, Naomi Abe et al. · Molecular Cancer Therapeutics · 2018 · 85 citations

Medicine, Oncology, Pharmacology +17

Structures of the PKC-ι kinase domain in its ATP-bound and apo forms reveal defined structures of residues 533–551 in the C-terminal tail and their roles in ATP binding

Tetsuo Takimura, Kenji Kamata, Kazuhiro Fukasawa et al. · Acta Crystallographica Section D Biological Crystallography · 2010 · 49 citations

Life Sciences, Biochemistry, Molecular Biology +14

Hydrocarbons with a homoconjugated polyene system and their monoepoxy derivatives: Sex attractants of geometrid and noctuid moths distributed in Japan

Tetsu Ando, Hirokazu Ohsawa, Tadahiro Ueno et al. · Journal of Chemical Ecology · 1993 · 44 citations

Life Sciences, Biology, Entomology +12

Discovery of Futibatinib: The First Covalent FGFR Kinase Inhibitor in Clinical Use

Satoru Ito, Sachie Otsuki, Hirokazu Ohsawa et al. · ACS Medicinal Chemistry Letters · 2023 · 34 citations · Full text

Medicine, Oncology, Pharmacology +15

1–5 of 7